Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids

European Journal of Cancer

Volumn 45, Issue 13, 2009, Pages 2402-2411

  Lobjois, Valérie ^a   Frongia, Céline ^a   Jozan, Suzanne ^a   Truchet, Isabelle ^a   Valette, Annie ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

3D imaging; Cell cycle; Cytotoxicity; SAHA; Spheroids; Tumour microenvironment

Indexed keywords

CYCLIN A; HISTONE; KI 67 ANTIGEN; PROTEIN P21; VORINOSTAT;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL STRAIN HCT116; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROENVIRONMENT; MULTICELLULAR SPHEROID; PRIORITY JOURNAL; TUMOR SPHEROID;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; COLONIC NEOPLASMS; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; HYDROXAMIC ACIDS; KI-67 ANTIGEN; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 68749102106     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.026     Document Type: Article

References (34)

1. Desoize B., and Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Crit Rev Oncol Hematol 36 2-3 (2000) 193-207
2. Friedrich J., Ebner R., and Kunz-Schughart L.A. Experimental anti-tumour therapy in 3-D: spheroids-old hat or new challenge?. Int J Radiat Biol 83 11-12 (2007) 849-871
3. Sutherland R.M. Cell and environment interactions in tumour microregions: the multicell spheroid model. Science 240 4849 (1988) 177-184
4. Mellor H.R., Ferguson D.J., and Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer 93 3 (2005) 302-309
5. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13 6 (2001) 477-483
6. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 37 (2007) 5541-5552
7. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 26 9 (2007) 1351-1356
8. Piekarz R., and Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10 19 (2004) 2289-2298
9. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 1 (2007) 31-39
10. Munster P., Marchion D., Bicaku E., et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumours: a clinical and translational study. J Clin Oncol 25 15 (2007) 1979-1985
11. Wang S., Yan-Neale Y., Cai R., Alimov I., and Cohen D. Activation of mitochondrial pathway is crucial for tumour selective induction of apoptosis by LAQ824. Cell Cycle 5 15 (2006) 1662-1668
12. Takada Y., Gillenwater A., Ichikawa H., and Aggarwal B.B. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281 9 (2006) 5612-5622
13. Ungerstedt J.S., Sowa Y., Xu W.S., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 3 (2005) 673-678
14. Peart M.J., Tainton K.M., Ruefli A.A., et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63 15 (2003) 4460-4471
15. Zhu P., Huber E., Kiefer F., and Gottlicher M. Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. Cell cycle 3 10 (2004) 1240-1242
16. Del Duca D., Werbowetski T., and Del Maestro R.F. Spheroid preparation from hanging drops: characterization of a model of brain tumour invasion. J Neurooncol 67 3 (2004) 295-303
17. Truchet I., Jozan S., Baron S., et al. Estrogen and antiestrogen-dependent regulation of breast cancer cell proliferation in multicellular spheroids: influence of cell microenvironment. Int J Oncol 32 5 (2008) 1033-1039
18. Sauer H., Klimm B., Hescheler J., and Wartenberg M. Activation of p90RSK and growth stimulation of multicellular tumour spheroids are dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Faseb J 15 13 (2001) 2539-2541
19. 2+. Am J Physiol 272 5 Pt 2 (1997) R1677-R1683
20. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97 18 (2000) 10014-10019
21. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18 6 (2006) 609-615
22. Noh E.J., Lim D.S., Jeong G., and Lee J.S. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun 378 3 (2009) 326-331
23. Grabowski P., Kuhnel T., Muhr-Wilkenshoff F., et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 88 1 (2003) 115-119
24. Ruefli A.A., Ausserlechner M.J., Bernhard D., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98 19 (2001) 10833-10838
25. Arts J., Angibaud P., Marien A., et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoural activity against solid and haematological malignancies. Br J Cancer 97 10 (2007) 1344-1353
26. Xu W.S., Perez G., Ngo L., Gui C.Y., and Marks P.A. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumour effects. Cancer Res 65 17 (2005) 7832-7839
27. Shin H.J., Baek K.H., Jeon A.H., et al. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 22 25 (2003) 3853-3858
28. Warrener R., Beamish H., Burgess A., et al. Tumour cell-selective cytotoxicity by targeting cell cycle checkpoints. Faseb J 17 11 (2003) 1550-1552
29. Taddei A., Maison C., Roche D., and Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 3 2 (2001) 114-120
30. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63 13 (2003) 3637-3645
31. Burgess A., Ruefli A., Beamish H., et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23 40 (2004) 6693-6701
32. Burgess A.J., Pavey S., Warrener R., et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 60 4 (2001) 828-837
33. Tupper J., Greco O., Tozer G.M., and Dachs G.U. Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumour model. Cancer Gene Ther 11 7 (2004) 508-513
34. Nguyen D.M., Schrump W.D., Chen G.A., et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 10 5 (2004) 1813-1825